Robert G Bota, MD
Psychiatry · Costa Mesa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 29 years
- Graduated 1997
Offices
2 locations · Silvan Medical Consulting Inc · 2 clinicians in this group
Looking this up.
Hospitals listed: College Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bota’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A103585 · Current
Licensed to practise in California · since 2008 · expires 2027-08-31 · University of Medicine and Pharmacy 'Carol Davila'.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Psychiatry
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- College Medical CenterLong Beach, CAAcute Care Hospital · Proprietary · Has an emergency department57% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for College Medical Center
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 1 better, 3 the same, 0 worse of 4 measures. Readmissions: 0 better, 5 the same, 0 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.04 (0 to 2.12) · 185 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.47 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.7 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 384 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,485 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.52) · 1,504 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.39 (0.79 to 6) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.59 to 4.04) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.4) · 1,344 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.12 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.525 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 54 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -11.4 · 87 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 89 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 61 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.8) · 128 cases | No different | Jan 2022 – Dec 2024 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 64% |
| Staff "always" explained | 46% |
| Yes, staff "did" give patients this information | 70% |
| Yes, staff "did" give patients information about help after discharge | 71% |
| Doctors "always" explained things so they could understand | 54% |
| Doctors "always" listened carefully | 60% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 57% |
| Nurses "always" explained things so they could understand | 63% |
| Nurses "always" listened carefully | 64% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 57% |
| Staff "always" explained possible side effects | 35% |
| Yes, staff "did" give patients information about possible symptoms | 70% |
Original Medicare doctor bills
$118,156
Medicare paid this office $118,156 for 80 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 30 | $89,384 | $104 |
| Return visit (30+ min) | 33 | $7,173 | $93 |
| Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | 28 | $5,901 | $179 |
| Psychiatric diagnostic evaluation with medical services | 33 | $4,705 | $143 |
| Psychotherapy with evaluation and management visit, 30 minutes | 31 | $4,581 | $56 |
See all 6 services
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 30 | $89,384 | $104 |
| Return visit (30+ min) | 33 | $7,173 | $93 |
| Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | 28 | $5,901 | $179 |
| Psychiatric diagnostic evaluation with medical services | 33 | $4,705 | $143 |
| Psychotherapy with evaluation and management visit, 30 minutes | 31 | $4,581 | $56 |
| Short return visit (20+ min) | 20 | $2,354 | $65 |
Who their Medicare patients are
80 Original Medicare patients in 2024. Average age 71 · Women 59% · Also on Medicaid 33% · Health risk score 1.19. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: Depression 75% · High blood pressure 68% · Diabetes 28% · Coronary heart disease 19% · Dementia 19% · Chronic kidney disease 16% · COPD 14%.
The office billed $1,309,973, Medicare allowed $152,794 and paid $118,156; for 1,185 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 80 | 1,185 | 71 | 1.19 | $1,309,973 | $118,156 |
| 2023 | 87 | 906 | 71 | 1.33 | $858,109 | $95,038 |
| 2022 | 101 | 1,081 | 71 | 1.34 | $1,022,234 | $117,385 |
| 2021 | 22 | 331 | 71 | 1.69 | $255,195 | $34,704 |
| 2020 | 16 | 138 | 70 | 1.72 | $39,130 | $11,888 |
| 2019 | 142 | 595 | 57 | 2.10 | $289,844 | $43,770 |
| 2018 | 140 | 679 | 58 | 1.69 | $274,235 | $45,372 |
| 2017 | 124 | 520 | 57 | 1.63 | $156,032 | $29,686 |
| 2016 | 110 | 502 | 56 | 1.71 | $144,257 | $31,170 |
| 2015 | 151 | 885 | 53 | 1.84 | $183,150 | $55,884 |
| 2014 | 43 | 285 | 53 | 1.76 | $58,962 | $18,949 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 21 | $57,149 | $105 |
| Return visit (30+ min) | 56 | $17,190 | $102 |
| Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | 17 | $5,338 | $191 |
| Psychotherapy with evaluation and management visit, 30 minutes | 25 | $3,960 | $57 |
| New patient visit (60+ min) | 21 | $3,646 | $174 |
| Short return visit (20+ min) | 21 | $2,755 | $67 |
| Psychiatric diagnostic evaluation with medical services | 16 | $2,726 | $151 |
2022: 8 services
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 28 | $66,093 | $107 |
| Return visit (30+ min) | 49 | $17,460 | $111 |
| New patient visit (60+ min) | 43 | $7,947 | $185 |
| Psychotherapy with evaluation and management visit, 30 minutes | 25 | $6,139 | $59 |
| Psychiatric diagnostic evaluation with medical services | 37 | $6,100 | $165 |
| Short return visit (20+ min) | 22 | $4,645 | $76 |
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent motor threshold redetermination with delivery and management | 17 | $4,308 | $172 |
| Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | 21 | $3,850 | $183 |
2021: 2 services
| Return visit (30+ min) | 13 | $8,321 | $111 |
| Psychiatric diagnostic evaluation with medical services | 13 | $2,226 | $171 |
2019: 6 services
| Return visit (30+ min) | 53 | $5,867 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $5,559 | $62 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $4,901 | $33 |
| Short return visit (20+ min) | 54 | $3,345 | $51 |
| Psychiatric diagnostic evaluation with medical services | 16 | $1,985 | $117 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,930 | $92 |
2018: 7 services
| Return visit (30+ min) | 68 | $8,497 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $7,673 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $6,739 | $32 |
| Psychiatric diagnostic evaluation with medical services | 23 | $3,288 | $122 |
| Short return visit (20+ min) | 40 | $3,244 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,178 | $156 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,958 | $89 |
2017: 8 services
| Return visit (30+ min) | 58 | $7,977 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $5,365 | $58 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $4,241 | $31 |
| Short return visit (20+ min) | 41 | $3,296 | $49 |
| Psychiatric diagnostic evaluation with medical services | 17 | $1,757 | $103 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,570 | $87 |
| Psychotherapy with evaluation and management visit, 30 minutes | 21 | $1,219 | $38 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,134 | $71 |
2016: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $9,214 | $59 |
| Return visit (30+ min) | 36 | $5,454 | $81 |
| Short return visit (20+ min) | 36 | $3,527 | $61 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 31 | $3,120 | $33 |
| Psychotherapy with evaluation and management visit, 30 minutes | 29 | $2,764 | $52 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,264 | $91 |
| Psychiatric diagnostic evaluation with medical services | 18 | $2,013 | $112 |
2015: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $31,126 | $62 |
| Return visit (30+ min) | 47 | $7,368 | $89 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $4,800 | $33 |
| Hospital discharge day management, more than 30 minutes | 28 | $3,025 | $92 |
| Short return visit (20+ min) | 36 | $2,810 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,580 | $89 |
| Psychiatric diagnostic evaluation with medical services | 11 | $1,354 | $123 |
| Psychotherapy with evaluation and management visit, 30 minutes | 15 | $1,098 | $55 |
2014: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $13,877 | $61 |
| Return visit (30+ min) | 19 | $2,335 | $90 |
Medicaid work
$2,266 in 2019
Medicaid paid $2,266 for 53 billed services this clinician did in 2019, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Comprehensive medication services, per 15 minutes | 53 | $2,266 |
| 2019 | 53 | 1 | 15 | $2,266 |
Drugs they prescribed that Part D paid
$52,365
Pharmacies billed $52,365 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 318) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
281 generic and 37 brand-name prescriptions · $52,365 in drug cost · 18 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dayvigo | 13 | $4,306 | $331 |
| Tranylcypromine Sulfate | 11 | $893 | $81 |
| Bupropion Xl | 19 | $587 | $31 |
| Duloxetine | 25 | $539 | $22 |
| Buspirone | 15 | $494 | $33 |
See all 11 drugs
| Dayvigo | 13 | $4,306 | $331 |
| Tranylcypromine Sulfate | 11 | $893 | $81 |
| Bupropion Xl | 19 | $587 | $31 |
| Duloxetine | 25 | $539 | $22 |
| Buspirone | 15 | $494 | $33 |
| Escitalopram | 14 | $381 | $27 |
| Clonazepam | 25 | $300 | $12 |
| Sertraline | 22 | $229 | $10 |
| Dextroamphetamine-Amphetamine | 14 | $220 | $16 |
| Alprazolam | 25 | $154 | $6 |
| Lorazepam | 13 | $100 | $8 |
Year by year
| 2024 | 318 | 40 | 0% (0) | 12% | $52,365 |
| 2023 | 379 | 45 | 0% (0) | 8% | $34,290 |
| 2022 | 263 | 48 | 0% (0) | None | $12,742 |
| 2021 | 218 | 29 | 0% (0) | 5% | $14,138 |
| 2020 | 44 | 11 | 0% (0) | None | $1,511 |
| 2019 | 96 | 32 | None | 11% | $11,201 |
| 2018 | 167 | 40 | None | 11% | $16,484 |
| 2017 | 165 | 32 | None | None | $12,293 |
| 2016 | 97 | 21 | None | None | $2,499 |
| 2015 | 226 | 72 | None | 12% | $9,176 |
| 2014 | 1,396 | 245 | 0% (0) | 12% | $132,802 |
| 2013 | 1,979 | 323 | None | 15% | $145,449 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Aripiprazole | 15 | $1,961 | $131 |
| Olanzapine | 23 | $1,951 | $85 |
| Bupropion Xl | 11 | $955 | $87 |
| Duloxetine | 27 | $805 | $30 |
| Dextroamphetamine-Amphetamine | 14 | $783 | $56 |
| Clonazepam | 28 | $568 | $20 |
| Buspirone | 24 | $389 | $16 |
| Alprazolam | 26 | $319 | $12 |
| Sertraline | 27 | $300 | $11 |
| Mirtazapine | 11 | $250 | $23 |
| Lorazepam | 23 | $207 | $9 |
| Escitalopram | 13 | $153 | $12 |
2022: 9 drugs
| Bupropion Xl | 18 | $1,862 | $103 |
| Dextroamphetamine-Amphetamine | 13 | $660 | $51 |
| Buspirone | 16 | $459 | $29 |
| Alprazolam | 26 | $316 | $12 |
| Mirtazapine | 12 | $233 | $19 |
| Trazodone | 14 | $159 | $11 |
| Risperidone | 11 | $142 | $13 |
| Sertraline | 26 | $126 | $5 |
| Lorazepam | 11 | $39 | $4 |
2021: 7 drugs
| Bupropion Xl | 16 | $1,904 | $119 |
| Dextroamphetamine-Amphetamine | 14 | $791 | $57 |
| Olanzapine | 22 | $687 | $31 |
| Trazodone | 21 | $329 | $16 |
| Mirtazapine | 18 | $298 | $17 |
| Clonazepam | 18 | $122 | $7 |
| Lorazepam | 15 | $68 | $5 |
2019: 1 drug
| Quetiapine | 12 | $126 | $11 |
2018: 2 drugs
| Divalproex Sodium Er | 13 | $1,093 | $84 |
| Risperidone | 11 | $135 | $12 |
2017: 1 drug
| Quetiapine Fumarate Er | 11 | $6,134 | $558 |
2016: 1 drug
| Quetiapine | 11 | $100 | $9 |
2015: 3 drugs
| Bupropion Xl | 11 | $1,136 | $103 |
| Mirtazapine | 13 | $305 | $23 |
| Trazodone | 11 | $132 | $12 |
2014: 37 drugs
| Abilify | 31 | $51,132 | $1,649 |
| Ziprasidone | 19 | $8,342 | $439 |
| Bupropion Xl | 51 | $7,056 | $138 |
| Adderall Xr | 13 | $4,766 | $367 |
| Duloxetine | 18 | $3,541 | $197 |
| Quetiapine | 38 | $3,470 | $91 |
| Venlafaxine Hcl Er | 51 | $3,389 | $66 |
| Perphenazine | 32 | $2,302 | $72 |
| Mirtazapine | 62 | $2,299 | $37 |
| Sertraline | 64 | $2,055 | $32 |
| Triazolam | 31 | $1,714 | $55 |
| Buspirone | 47 | $1,572 | $33 |
| Amphetamine Salt Combo | 13 | $1,369 | $105 |
| Fluoxetine | 82 | $1,356 | $17 |
| Loxapine | 19 | $1,281 | $67 |
| Alprazolam | 114 | $1,217 | $11 |
| Oxcarbazepine | 12 | $1,212 | $101 |
| Oxazepam | 14 | $1,136 | $81 |
| Trazodone | 81 | $1,111 | $14 |
| Fluvoxamine Maleate | 13 | $1,083 | $83 |
| Lorazepam | 70 | $971 | $14 |
| Risperidone | 31 | $967 | $31 |
| Clonazepam | 65 | $940 | $14 |
| Doxepin | 21 | $754 | $36 |
| Escitalopram | 29 | $701 | $24 |
| Temazepam | 39 | $676 | $17 |
| Paroxetine | 29 | $527 | $18 |
| Hydroxyzine Pamoate | 11 | $446 | $41 |
| Olanzapine | 16 | $439 | $27 |
| Zolpidem | 30 | $390 | $13 |
| Lamotrigine | 20 | $363 | $18 |
| Citalopram Hbr | 30 | $361 | $12 |
| Diazepam | 29 | $355 | $12 |
| Amitriptyline | 16 | $286 | $18 |
| Benztropine Mesylate | 19 | $259 | $14 |
| Estazolam | 12 | $252 | $21 |
| Propranolol | 17 | $143 | $8 |
2013: 42 drugs
| Abilify | 48 | $49,260 | $1,026 |
| Ziprasidone | 33 | $13,246 | $401 |
| Bupropion Xl | 89 | $11,868 | $133 |
| Cymbalta | 13 | $7,792 | $599 |
| Venlafaxine Hcl Er | 62 | $5,338 | $86 |
| Adderall Xr | 12 | $3,828 | $319 |
| Mirtazapine | 99 | $3,436 | $35 |
| Olanzapine | 27 | $3,092 | $115 |
| Quetiapine | 46 | $2,965 | $64 |
| Sertraline | 95 | $2,908 | $31 |
| Divalproex | 23 | $2,516 | $109 |
| Amphetamine Salt Combo | 24 | $2,012 | $84 |
| Alprazolam | 183 | $1,860 | $10 |
| Lorazepam | 113 | $1,699 | $15 |
| Temazepam | 71 | $1,524 | $21 |
| Bupropion Hcl Sr | 23 | $1,504 | $65 |
| Escitalopram | 56 | $1,427 | $25 |
| Triazolam | 31 | $1,421 | $46 |
| Methylphenidate | 16 | $1,417 | $89 |
| Fluoxetine | 88 | $1,347 | $15 |
| Trazodone | 97 | $1,293 | $13 |
| Fluvoxamine Maleate | 15 | $1,201 | $80 |
| Clonazepam | 82 | $1,157 | $14 |
| Thiothixene | 16 | $1,087 | $68 |
| Lamotrigine | 43 | $1,065 | $25 |
| Oxazepam | 12 | $1,014 | $85 |
| Haloperidol | 13 | $970 | $75 |
| Loxapine | 17 | $959 | $56 |
| Zolpidem | 88 | $929 | $11 |
| Buspirone | 45 | $851 | $19 |
| Risperidone | 42 | $844 | $20 |
| Bupropion | 15 | $774 | $52 |
| Lithium Carbonate | 20 | $749 | $37 |
| Diazepam | 49 | $718 | $15 |
| Paroxetine | 42 | $611 | $15 |
| Citalopram Hbr | 45 | $506 | $11 |
| Estazolam | 17 | $434 | $26 |
| Hydroxyzine Pamoate | 12 | $360 | $30 |
| Benztropine Mesylate | 29 | $342 | $12 |
| Doxepin | 25 | $337 | $13 |
| Amitriptyline | 24 | $330 | $14 |
| Propranolol | 13 | $111 | $9 |
Money from drug and device companies
$774 in 2025
| 2025 | 9 | 15 | None | $774 |
| 2024 | 5 | 8 | None | $492 |
| 2023 | 10 | 14 | None | $789 |
| 2022 | 4 | 6 | None | $151 |
| 2020 | 2 | 2 | None | $157 |
| 2019 | 2 | 3 | None | $147 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Neurocrine BioSciences | Ingrezza | $216 | 3 payments
|
| Janssen Pharmaceuticals | Spravato | $177 | 3 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $146 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $82 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $55 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $35 | 1 payment
|
See all 15 published payments
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-03 | Caplyta | $30 |
| Neurocrine BioSciences | Meals · 2025-12-03 | Ingrezza | $113 |
| Janssen Pharmaceuticals | Meals · 2025-09-15 | Invega Sustenna | $6 |
| Janssen Pharmaceuticals | Meals · 2025-09-15 | Invega Sustenna | $27 |
| Supernus Pharmaceuticals | Meals · 2025-08-01 | None | $20 |
| Otsuka America Pharmaceutical | Meals · 2025-07-10 | Rexulti | $26 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-02 | Caplyta | $25 |
| Otsuka America Pharmaceutical | Meals · 2025-06-23 | Abilify Maintena | $120 |
| Neurocrine BioSciences | Meals · 2025-06-04 | Ingrezza | $26 |
| Janssen Pharmaceuticals | Meals · 2025-05-14 | Spravato | $144 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-28 | Cobenfy | $35 |
| Abbvie | Meals · 2025-04-17 | Vraylar | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-13 | None | $82 |
| Neurocrine BioSciences | Meals · 2025-02-13 | Ingrezza | $77 |
| Teva Pharmaceuticals USA | Meals · 2025-02-03 | Uzedy | $19 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $492
| Neurocrine Biosciences | None | $238 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $194 | 2 payments
|
| Corium | Azstarys | $24 | 2 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $22 | 1 payment
|
| Lundbeck | Rexulti | $14 | 1 payment
|
2023: $789
| Iti | Caplyta | $142 | 1 payment
|
| Neurocrine Biosciences | None | $140 | 2 payments
|
| Alkermes | Aristada | $117 | 1 payment
|
| Axsome Therapeutics | Auvelity | $100 | 1 payment
|
| Janssen Pharmaceuticals | Invega Sustenna | $95 | 3 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Abilify Asimtufii | $89 | 1 payment
|
| Corium | Azstarys | $49 | 2 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $20 | 1 payment
|
| Noven Therapeutics | Secuado | $19 | 1 payment
|
| Lundbeck | Rexulti | $18 | 1 payment
|
2022: $151
| Sunovion Pharmaceuticals | Latuda | $60 | 2 payments
|
| Noven Therapeutics | Secuado | $43 | 2 payments
|
| Iti | Caplyta | $29 | 1 payment
|
| Neuronetics | Neurostar Tms Therapy System | $19 | 1 payment
|
2020: $157
| Janssen Pharmaceuticals | Spravato | $125 | 1 payment
|
| Neuronetics | Neurostar Tms Therapy | $33 | 1 payment
|
2019: $147
| Novocure | Oncology | $133 | 2 payments
|
| West Therapeutics Development | Lazanda | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · An Open-Label Study To Assess the Long-Term Safety, Tolerability, and Efficacy of Karxt in De Novo Subjects With Dsm-5 Schizophrenia · 2024 | Their institution | $816,289 |
| Teva Pharmaceuticals USA, Inc. · A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With An Open-Label, Long-Term Safety Phase To Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (Tv-44749) for Subcutaneous Use As Treatment of Adult Patients With Schizophrenia · 2023 | Their institution | $780,955 |
| Hoffmann-La Roche Limited · Acute Schizophrenia Study · 2021 | Their institution | $411,145 |
| E.R. Squibb & Sons, L.L.C. · An Open-Label Study To Assess the Long-Term Safety, Tolerability, and Efficacy of Karxt in De Novo Subjects With Dsm-5 Schizophrenia · 2025 | Their institution | $294,276 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Karxt for the Treatment of Manic Episodes in Bipolar-I Disorder · 2025 | Their institution | $214,566 |
| Hoffmann-La Roche Limited · Acute Schizophrenia Study · 2023 | Their institution | $175,263 |
| Teva Pharmaceuticals USA, Inc. · A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With An Open-Label, Long-Term Safety Phase To Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (Tv-44749) for Subcutaneous Use As Treatment of Adult Patients With Schizophrenia · 2024 | Their institution | $146,515 |
| Merck Sharp & Dohme Corporation · A Phase 2b Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of Mk-8189 in Participants Experiencing An Acute Episode of Schizophrenia · 2021 | Their institution | $141,574 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder · 2020 | Their institution | $124,965 |
| BioXcel Therapeutics, Inc. · Bxcl501401 · 2025 | Their institution | $118,368 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Pocc Study in Patients With Ptsd · 2022 | Their institution | $88,220 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Pocc Study in Patients With Ptsd · 2023 | Their institution | $81,430 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2022 | Their institution | $71,894 |
| Axsome Therapeutics, Inc. · A Randomized, Double-Blind, Active-Controlled Study of Axs-05 for the Prevention of Relapse of Depressive Symptoms · 2024 | Their institution | $71,244 |
| Axsome Therapeutics, Inc. · A Randomized, Double-Blind, Active-Controlled Study of Axs-05 for the Prevention of Relapse of Depressive Symptoms · 2025 | Their institution | $61,425 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2021 | Their institution | $54,697 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2020 | Their institution | $51,140 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder · 2021 | Their institution | $44,615 |
| Sumitomo Pharma America, Inc. · A Clinical Study That Will Evaluate How Well Sep-363856 Works and How Safe It Is in People With Schizophrenia That Switch To Sep-363856 From Their Current Antipsychotic Medication · 2024 | Their institution | $43,140 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2023 | Their institution | $42,994 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder · 2024 | Their institution | $41,406 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Pocc Study in Patients With Ptsd · 2024 | Their institution | $34,565 |
| Hoffmann-La Roche Limited · Acute Schizophrenia Study · 2022 | Their institution | $33,841 |
| Sumitomo Pharma America, Inc. · A Clinical Study That Will Evalute How Well Sep-363856 Works and How Safe It Is in People With Schizophrenia That Switch To Sep-363856 From Their Current Antisychotic Medication · 2023 | Their institution | $28,575 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Open-Label Trial To Evaluate the Safety and Tolerability of Brexpiprazole · 2020 | Their institution | $27,368 |
| Teva Pharmaceuticals USA, Inc. · A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With An Open-Label, Long-Term Safety Phase To Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (Tv-44749) for Subcutaneous Use As Treatment of Adult Patients With Schizophrenia · 2025 | Their institution | $26,432 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Open-Label Extension Study To Assess the Long-Term Safety of Karxt for the Treatment of Mania Or Mania With Mixed Features in Bipolar-I Disorder · 2025 | Their institution | $23,968 |
| JAZZ PHARMACEUTICALS INC. · A Multicenter Phase 2 12-Week Double-Blind Placebo-Controlled Randomized Parallel-Group Study of Jzp150 for the Treatment of Posttraumatic Stress Disorder · 2022 | Their institution | $21,550 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2023 | Their institution | $20,023 |
| E.R. Squibb & Sons, L.L.C. · An Open-Label, Phase 1, Single Ascending Dose Finding Study To Characterize the Safety, Tolerability, and Pharmacokinetics of Karxt Intramuscular Formulations in Participants With Schizophrenia · 2025 | Their institution | $17,173 |
| F. Hoffmann-La Roche AG · Acute Schizophrenia Study · 2022 | Their institution | $16,225 |
| F. Hoffmann-La Roche AG · P2 Study of Balovaptan in Ptsd · 2023 | Their institution | $14,000 |
| Sumitomo Pharma America, Inc. · A 24-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of Sep-363856 in Subjects With Schizophrenia Switched From Typical Or Atypical Antipsychotic Agents Ole. · 2025 | Their institution | $11,828 |
| Supernus Pharmaceuticals, Inc. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Nv-5138 in Adults With Treatment Resistant Depression · 2022 | Their institution | $9,500 |
| Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2022 | Their institution | $8,500 |
| BioXcel Therapeutics, Inc. · Bxcl501401 · 2024 | Their institution | $6,450 |
| Merck Sharp & Dohme Corporation · A Phase 2b Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of Mk-8189 in Participants Experiencing An Acute Episode of Schizophrenia · 2020 | Their institution | $5,611 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Pocc Study in Patients With Ptsd · 2023 | Their institution | $4,361 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Open-Label Trial To Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Borderline Personality Disorder. · 2022 | Their institution | $3,048 |
| Supernus Pharmaceuticals, Inc. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Nv-5138 in Adults With Treatment Resistant Depression · 2024 | Their institution | $3,000 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Pocc Study in Patients With Ptsd · 2022 | Their institution | $2,564 |
| Celgene Corporation · Mrz-108 Phase 1, Multicenter, Open-Label, Dose-Escalation, Combination Study of Mrz & Bevacizumab in Bevacizumab-NaïVe Subjects With Who Grade IV Malignant Glioma Followed By Phase 2 Studies of Single Agent Mrz & Combination Mrz & Bevacizumab (Ca070-P01) (Mrz-108) · 2019 | This clinician | $2,288 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · Brexpiprazole As Combination Therapy With Sertraline in Treatment of Adults With Ptsd · 2020 | This clinician | $1,617 |
| Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2023 | Their institution | $1,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2024 | Their institution | $755 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Open-Label Trial To Evaluate the Safety and Tolerability of Brexpiprazole · 2021 | Their institution | $596 |
Professional record
- NPI
- 1407990773
- Licence
- CA A103585California A103585: Current · expires 2027-08-31
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 3151 Airway Ave Bldg R, Costa Mesa, CA, 92626
- NPI first listed
- 2007-02-19
- NPI last updated
- 2025-01-17
- NPI record certified
- 2025-01-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 14441 W Mcdowell Rd Ste B102, Goodyear, AZ, 85395